Table 2 Association of EGFR expression and clinicopathological features
Cutoff | Below cutoff N (%) | Above cutoff N (%) | P -value | |
|---|---|---|---|---|
Predicting CR | ||||
CR | 18% | 6 (14.6) | 21 (51.2) | <0.001 |
PR or NR | 35 (85.4) | 20 (48.8) | ||
Predicting CR or PR | ||||
CR or PR | 15% | 20 (51.3) | 34 (79.1) | 0.008 |
NR | 19 (48.7) | 9 (20.9) | ||
T stage | ||||
Early (T1+T2) | 85% | 118 (24.1) | 14 (15.4) | 0.069 |
Late (T3+T4) | 372 (75.9) | 77 (84.6) | ||
N stage | ||||
N0 | 75% | 244 (52.4) | 54 (50.9) | 0.792 |
>N0 | 222 (47.6) | 52 (49.1) | ||
Tumour grade | ||||
G1+G2 | 82% | 431 (87.8) | 89 (94.7) | 0.051 |
G3 | 60 (12.2) | 5 (5.3) | ||
Vascular invasion | ||||
Presence | 80% | 133 (27.6) | 30 (29.1) | 0.753 |
Absence | 349 (72.4) | 73 (70.9) | ||
10-year survival | ||||
Median (95% CI) (months) | 85% | 87.0 (69.0–103.0) | 35.0 (23.0–58.0) | <0.001 |
